Clinical Trials Logo

Clinical Trial Summary

Ureteric stents are used often following ureteroscopy for prevention of obstruction from edema and/or stone fragments.

Up to 75% of patients experience pain following stenting, as well as lower urinary tract symptoms (LUTS) such as finding blood in the urine, voiding often, the need to urinate quickly resulting in a significant source of morbidity. The negative impact of stents results in a significant impact on health related quality of life.

There is no standard of care for managing ureteric stent pain and lower urinary tract symptoms following surgery. A combination of α-blockers, antimuscarinics, acetaminophen, nonsteroidal anti-inflammatory drugs and opioids are currently the mainstay for treatment of post-operative pain and LUTS following stenting.

Mirabegron is a beta-agonist that mediate relaxation of the detrusor muscle and has been useful in treating overactive bladder (OAB) which has similar symptoms to patients with an ureteric stent in place. Our goal is to assess if mirabegron can improve symptoms and decrease the need for additional pain medications.

The investigators hypothesize that Mirabegron is effective in decreasing ureteral stent related LUTS and pain.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04286152
Study type Interventional
Source St. Michael's Hospital, Toronto
Contact Daniela Ghiculete, MD, MSc
Phone 416-864-6060
Email Daniela.Ghiculete@unityhealth.to
Status Recruiting
Phase Phase 3
Start date February 3, 2020
Completion date June 30, 2021

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04746378 - PRedictive Accuracy of Initial Stone Burden Evaluation.
Recruiting NCT05100017 - Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure N/A
Recruiting NCT03692715 - Antibiotic Prophylaxis Before Shock Wave Lithotripsy Phase 4
Completed NCT02547805 - Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days Phase 2
Completed NCT02289755 - Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria Phase 2
Completed NCT01650935 - Comparison of DASH With Oxalate Restricted Diet on Urine in Recurrent Stone Formers With Hyperoxaluria N/A
Completed NCT01690039 - Influence of Polymorphisms in the ATP6V1 Gene of the V-ATPase on the Development of Incomplete Distal Renal Tubular Acidosis
Completed NCT01295879 - Vitamin D Repletion in Stone Formers With Hypercalciuria Phase 4
Recruiting NCT05014178 - Kidney Sodium Functional Imaging
Not yet recruiting NCT06199102 - The High Initial Dose of Monitored Vitamin D Supplementation in Preterm Infants. N/A
Recruiting NCT04367155 - Efficacy of Tranexamic Acid on Blood Loss During Percutaneous Nephrolithotomy. N/A
Recruiting NCT04374188 - Efficacy of Ciprofloxacin Therapy in Avoidance of Sepsis in Patient Undergoing Percutanous Nephrolithotomy N/A
Recruiting NCT05701098 - SOUND Pivotal Trial - (Sonomotion stOne comminUtion resoNance ultrasounD) N/A
Recruiting NCT04389853 - Mini-PNCL vs fURS in Management of Nephrolithiasis N/A
Completed NCT03348228 - Effect of Hydroxycitrate on Urine Chemistry N/A
Completed NCT05350423 - Trial Assessing Renal Damage During Ureteroscopy N/A
Completed NCT03454139 - Subcostal TAP Block For Percutaneous Nephrolithotomy N/A
Recruiting NCT02279927 - Prospective Comparison Between Different Laser Settings for Ureteral \ Kidney Stones Treatment During Ureteroscopy N/A
Completed NCT02276924 - Diagnostic Relevance of Laser Confocal Microscopy for the Screening of Upper Urinary Tract Tumors N/A
Completed NCT00159393 - Percutaneous Nephrolithotomy: A Registry and Database